S-268019

In this article, we will thoroughly explore the topic of S-268019 and analyze its different aspects from a critical and objective perspective. S-268019 is a topic that has generated great interest and debate in modern society, and it is important to examine it thoroughly to understand its impact on our daily lives. Throughout this article, we will address different points of view and opinions on S-268019, and offer a comprehensive and balanced view that allows the reader to form their own opinion on the matter. From its origins to its future implications, we will delve into all the nuances of S-268019 to provide a complete overview of this topic that is so relevant today.

S-268019
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
2024
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Society
virus icon COVID-19 portal

S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.

A study in non-human primates published in 2022 concluded S-268109-b demonstrated efficacy in a SARS-CoV-2 challenge experiment, although neutralizing antibodies against the Omicron variant were reduced.

In a phase 1/2 clinical trial in Japan, the developers concluded reactions to the vaccine were mild, and neutralizing antibodies were similar to those in people who had recovered from Covid-19. A phase 3 trial planned for 54,915 participants began in December 2021 in Vietnam.

Preliminary results of a phase 2/3 trial using S-268019-b as a booster dose after two doses of the BNT162b2 vaccine by Pfizer concluded the vaccine was non-inferior to a booster dose of BNT162b2.

References

  1. ^ "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 21 March 2021.
  2. ^ "A Phase 2/3 Study of S-268019". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 20 October 2021.
  3. ^ Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki NM, et al. (July 2022). "Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys". Vaccine. 40 (31): 4231–4241. doi:10.1016/j.vaccine.2022.05.081. PMC 9167832. PMID 35691872.
  4. ^ Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, et al. (June 2022). "Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings". Vaccine. 40 (27): 3721–3726. doi:10.1016/j.vaccine.2022.04.054. PMC 9122779. PMID 35606235.
  5. ^ "A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Cross-over Study to Evaluate the Efficacy, Safety, and Immunogenicity of S-268019 for the Prevention of COVID-19". ClinicalTrials.gov. National Institutes of Health. 26 July 2022. Retrieved 19 September 2022.
  6. ^ Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, et al. (July 2022). "Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study". Vaccine. 40 (32): 4328–4333. doi:10.1016/j.vaccine.2022.06.032. PMC 9212435. PMID 35738968.
Scholia has a profile for S-268019 (Q110269731).
Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia